Increased serum-soluble interleukin-2 receptor in burn patients: Characterization and effects on the immune system

Human Immunology

Volumn 61, Issue 3, 2000, Pages 233-246

  Jobin, Nathalie ^a   Garrel, Dominique ^a   Bernier, Jacques ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Burn, interleukin 6; Inflammation; Interleukin 2; Natural killer; Soluble interleukin 2 receptors; TH1; TH2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; OKT 3; PHYTOHEMAGGLUTININ; PLASMA PROTEIN;

ADULT; ARTICLE; BURN; CELL PROLIFERATION; CLINICAL ARTICLE; FAT INTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; WESTERN BLOTTING;

ADOLESCENT; ADULT; BURNS; CD4-POSITIVE T-LYMPHOCYTES; DIET; DIETARY FATS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MITOGENS; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-2; SOLUBILITY; T-LYMPHOCYTES;

EID: 0034000487     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00133-0     Document Type: Article

References (88)

1. Nelson B.H., Willerford D.M. Biology of the interleukin-2 receptor. Adv Immunol. 70:1998;1.
2. Sharon M., Klausner R.D., Cullen B.R., Chizzonite R., Leonard W.J. Novel interleukin-2 receptor subunit detected by cross-linking under high affinity conditions. Science. 234:1986;859.
3. Kondo S., Shimizu A., Saito Y., Kinoshita M., Honjo T. Molecular basis for two different affinity states of the interleukin 2 receptor affinity conversion model. Proc Natl Acad Sci USA. 83:1986;9026.
4. Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T. Interleukin-2 receptor beta chain gene generation of three receptor forms by cloned human alpha and beta chain cDNA's . Science. 244:1989;551.
5. Takeshita T., Asao H., Suzuki J., Sugamura K. An associated molecule, p64, with high-affinity interleukin 2 receptor. Int Immunol. 2:1990;477.
6. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K. Cloning of the gamma chain of the human IL-2 receptor. Science. 257:1992;379.
7. Taniguchi T., Minami Y. The IL-2/IL-2 receptor system a current overview . Cell. 73:1993;5.
8. Kamio M., Uchiyama T., Arima N., Itoh K., Ishikawa T., Hori T., Uchino H. Role of α chain-IL-2 complex in the formation of the ternary complex of IL-2 and high-affinity IL-2 receptor. Int Immunol. 2:1990;521.
9. Nelson B.H., Lord J.D., Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature. 369:1994;333.
10. Loughnan M.S., Nossal G.J.V. A regulatory role for the soluble IL-2 receptor via competition with the p75 cell-surface form of the receptor for IL-2. J Mol Cell Immunol. 4:1990;307.
11. Giri J.G., Kumaki S., Ahdieh M., Friend D.J., Loomis A., Shanebeck K., DuBose R., Cosman D., Park L.S., Anderson D.M. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14:1995;3654.
12. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor function, and clinical application . Ann Intern Med. 113:1990;619.
13. Cinat M., Waxman K., Vaziri N.D., Daughters K., Yousefi S., Scannell G., Tominaga G.T. Soluble cytokine receptors and receptor antagonists are sequentially released after trauma. J Trauma. 39:1995;112.
14. Matsumoto K., Taki F., Miura M., Matsuzaki M., Takagi K. Serum levels of soluble IL-2R, IL-4, and soluble Fc epsilon RII in adult bronchial asthma. Chest. 105:1994;681.
15. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 135:1985;3172.
16. Karlsson H., Nassberger L. Influence of compounds affecting synthesis, modification and transport of proteins on the expression and release of interleukin-2 receptor. Immunol Cell Biol. 73:1995;81.
17. Rubin L.A., Jay G., Nelson D.L. The released interleukin-2 receptor binds interleukin 2 efficiently. J Immunol. 137:1986;3841.
18. Sayar D., Ketzinel M., Gerez L., Silberberg C., Reshef A., Kaempfer R. Expression of the human IL-2 receptor on lymphocytes involves rapid turnover of its p55 α-Subunit (Tac). J Immunol. 145:1990;2946.
19. Mullberg J., Rauch C.T., Wolfson M.F., Castner B., Fitzner J.N., Otten-Evans C., Mohler K.M., Cosman D., Black R.A. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett. 401:1997;235.
20. Gallea-Robache S., Morand V., Millet S., Bruneau J.M., Bhatnagar N., Chouaib S., Roman-Roman S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine. 9:1997;340.
21. Loughnan M.S., Sanderson C.J., Nossal G.J.V. Soluble interleukin-2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc Natl Acad Sci USA. 85:1988;3115.
22. Müllberg J., Rauch C.T., Wolfson M.F., Castner B., Fitzner J.N., Otten-Evans C., Mohler K.M., Cosman D., Black R.A. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett. 401:1997;245.
23. Rimoldi D., Salvi S., Hartmann F., Schreyer M., Blum S., Zografos L., Plaisance S., Azzarone B., Carrel S. Expression of IL-2 receptors in human melanoma cells. Anticancer Res. 13:1993;555.
24. Alileche A., Plaisance S., Han D.S., Rubinstein E., Mingari C., Bellomo R., Jasmin C., Azzarone B. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene. 8:1993;1791.
25. Plaisance S., Rubinstein E., Alileche A., Han D.S., Sahraoui Y., Mingari M.C., Bellomo R., Rimoldi D., Colombo M.P., Jasmin C., et al. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer. 55:1993;64.
26. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G., Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer. 56:1994;853.
27. Boyano M.D., Garcia-Vazquez M.D., Gardeazabal J., Garcia de Galdeano A., Smith-Zubiaga I., Canavate M.L., Raton J.A., Bilbao I., Diaz-Perez J.L. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology. 54:1997;400.
28. Caruso C., Modica M.A., Candore G., Di Giulio C., Galluzzo A., Giordano C., Di Marco P., Gebbia V., Tamone Reyes M., Citarrella P. Soluble interleukin-2 receptor in vitro production by mononuclear cells from Hodgkin patients. Boll Ist Sieroter Milan. 69:1990;335.
29. Nelson D.L., Kurman C.C. Targeting human IL-2 receptors for diagnosis and therapy. Proc Soc Exp Biol Med. 206:1994;309.
30. Perkins J.D., Nelson D.L., Rakela J., Grambsch P.M., Krom R.A. Soluble interleukin 2 receptor level in liver allograft recipients an indicator of rejection . Transplant Proc. 21:1989;2275.
31. Honda M., Kitamura K., Matsuda K., Yokota Y., Yamamoto N., Mitsuyasu R., Chermann J.C., Tokunaga T. Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced diseases and its characterization. J Immunol. 142:1989;4248.
32. Honda M., Kitamura K., Mizutani Y., Oishi M., Arai M., Okura T., Igarahi K., Yasukawa K., Hirano T., Kishimoto T., et al. Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol. 145:1990;4059.
33. Greenberg S.J., Marcon L., Hurwitz B.J., Waldmann T.A., Nelson D.L. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med. 319:1988;1019.
34. Sharief M.K., Hentges R., Thompson E.J. The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis. J Neuroimmunol. 32:1991;43.
35. Elg S.A., Hill R.B., Heldman L., Ramakrishnan S. The in vitro effect on T cell function of soluble IL-2Rα from advanced ovarian cancer ascites. Gynecol Oncol. 66:1997;133.
36. Kay N.E., Burton J., Wagner D., Nelson D.L. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood. 72:1998;447.
37. Miossec P., Elhamiani M., Edmonds-Alt X., Sany J., Hirn M. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheum. 33:1990;1688.
38. Nielsen O.H., Ciardelli T., Wu Z., Langholz E., Kirman I. Circulating soluble interleukin-2 receptor α and β chain in inflammatory bowel disease. Am J Gastroenterol. 90:1995;1301.
39. Teodorczyk-Injeyan J.A., Sparkes B.G., Mills B.G., Falk R.E., Peters W.J. Increase of serum interleukin-2 receptor level in thermally injured patients. Clin Immunol Immunopathol. 51:1989;205.
40. Teodorczyk-Injeyan J.A., Sparkes B.G., Mills G.B., Peters W.J. Soluble interleukin 2-receptor α secretion is related to altered interleukin 2 production in thermally injured patients. Burns. 17:1991;290.
41. Delogu G., Casula A., Mancini P., Tellan G., Signore L. Serum neopterin and soluble interleukin-2 receptor for prediction of a shock state in gram-negative sepsis. J Crit Care. 10:1995;64.
42. Kullich W. Correlation of interleukin-2 receptor and neopterin secretion in rheumatoid arthritis. Clin Rheumatol. 12:1993;387.
43. Bodey B., Psenko V., Lipsey A.L., Kaiser H.E. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms. Anticancer Res. 16:1996;219.
44. Manoussakis M.N., Papadopoulos G.K., Drosos A.A., Moutsopoulos H.M. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol. 50:1989;321.
45. Burton J., Kay N.E. Does IL-2-receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia. 8:1994;92.
46. Artz E., Buric R., Stelzer G., Stalla J., Sauer J., Renner U., Stalla G.K. Interleukin involvement in anterior pituitary cell growth regulation effects of IL-2 and IL-6 . Endocrinology. 132:1993;459.
47. Arzt E., Stalla G.K. Cytokines autocrine and paracrine roles in the anterior pituitary . Neuroimmunomodulation. 3:1996;28.
48. Arzt E., Stelzer G., Renner U., Lange M., Müller O.A., Stalla G.K. Interleukin-2 and interleukin-2 receptor expression in human corticotropic adenoma and murine pituitary cell cultures. J Clin Invest. 90:1992;1944.
49. Krause A., Henrich A., Beckh K.H., Von Wichert P., Baerwald C. Correlation between density of beta 2-adrenergic receptors on peripheral blood mononuclear cells and serum levels of soluble interleukin-2 receptors in patients with chronic inflammatory diseases. Eur J Clin Invest. 22:1992;47.
50. Gooding R., Riches P., Dadian G., Moore J., Gore M. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer. 72:1995;452.
51. Peters M., Odenthal M., Schirmacher P., Blessing M., Fattori E., Ciliberto G., Meyer zum Buschenfelde K.H., Rose-John S. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. J Immunol. 159:1997;1474.
52. Miossec P., Elhamiani M., Edmonds-Alt X., Sany J., Hirn M. Functional studies of soluble low-affinity interleukin-2 receptors in rheumatoid synovial fluid. Arthritis Rheum. 33:1990;1688.
53. Pizzolo G., Vincenzi C., Vinante F., Rigo A., Veneri D., Chilosi M., Dusi S., Poli G., Zambello R., Semenzato G., et al. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proleferation in vitro. Cell Immunol. 141:1992;253.
54. Waldner C., Mongini C., Alvarez E., Roig I., Hajos S.E. Inhibitory activity of soluble IL-2R in sera, ascites and culture supernatants from murine leukaemic cells. Scand J Immunol. 40:1994;308.
55. Teodorczyk-Injeyan J.A., Sparkes B.G., Peters W.J. Serum interleukin-2 receptor as a possible mediator of immunosuppression after burn injury. J Burn Care Rehab. 10:1989;112.
56. Bernier J., Jobin N., Emptoz-Bonneton A., Pugeat M.M., Garrel D.R. Decreased corticosteroid-binding globulin in burn patients relationship with interleukin-6 and fat in nutritional support . Crit Care Med. 26:1998;452.
57. Garrel D.R., Razi M., Lariviere F., Jobin N., Naman N., Emptoz-Bonneton A., Pugeat M.M. Improved clinical status and length of care with low-fat nutrition support in burn patients. J Parenter Enteral Nutr. 19:1995;482.
58. Wu Z., Johnson K.W., Choi Y., Ciardelli T.L. Ligand binding analysis of soluble interleukin-2 receptor complexes by surface plasmon resonance. J Biol Chem. 270:1995;16045.
59. Chang L., Gusewitch G.A., Chritton D.B., Folz J.C., Lebeck L.K., Nehlsen-Cannarella S.L. Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods. 166:1993;45.
60. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680.
61. Schinkel C., Zimmer S., Durda P.J., Höcherl E., Herndon D.N., Faist E. Kinetics of soluble interleukin-2 receptor after mechanical and burn trauma. J Burn Care Rehab. 18:1997;210.
62. O'Sullivan S.T., O'Connor T.P.F. Immunosuppression following thermal injury the pathogenesis of immunodysfunction . Br J Plast Surg. 30:1997;615.
63. Trinchieri G., Matsumoto-Kobayashi M., Clark S.C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 160:1984;1147.
64. Miyasaka N., Darnell B., Baron S., Talal N. Interleukin 2 enhances natural killing of normal lymphocytes. Cell Immunol. 84:1984;154.
65. Domzig W., Stadler B.M., Herberman R.B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 130:1983;1970.
66. Kelso A. Th1 and Th2 subsets paradigms lost?Viewpoint . Immunol Today. 16:1995;374.
67. Pearlstein K.T., Palladino M.A., Welte K., Vilcek J. Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol. 80:1983;1.
68. Wagner F., Fischer N., Lersch C., Hart R., Dancygier H. Interleukin 4 inhibits the interleukin 2-induced production of its functional antagonist, interferon gamma. Immunol Lett. 21:1989;237.
69. Giacomini P., Fisher P.B., Duigou G.J., Gambari R., Natali P.G. Regulation of class II MHC gene expression by interferons insights into the mechanism of action of interferon (review) . Anticancer Res. 8:1988;1153.
70. Wong G.H., Clark-Lewis I., McKimm Breschkin L., Harris A.W., Schrader J.W. Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol. 131:1983;788.
71. Zwadlo-Klarwasser G., Kauhl W., Schmitz C., Hettich R. Influence of severe burn injury on the expression of RM 3/1 and HLA-DR antigens in human blood monocytes. J Burn Care Rehab. 17:1996;287.
72. Smith L.R., Brown S.L., Blalock J.E. Interleukin-2 induction of ACTH secretion presence of an interleukin-2 receptor alpha-chain-like molecule on pituitary cells . J Neuroimmunol. 21:1989;249.
73. Kronin V., Vremec D., Shortman K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int Immunol. 10:1998;237.
74. Faist E., Schinkel C., Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg. 20:1996;454.
75. Faist E., Mewes A., Baker C.C., Strasser T., Alkan S.S., Rieber P., Heberer G. Prostaglandin E2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma. J Trauma. 27:1987;837.
76. Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore-Donati L., Perona G., Berton G., Lestani M., Scarpa A., Agostini C., et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity . Blood. 70:1987;1530.
77. Pericle F., Liu J.H., Diaz J.I., Blanchard D.K., Wei S., Forni G., Djeu J.Y. Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol. 24:1994;440.
78. Djeu J.Y., Liu J.H., Wei S., Rui H., Pearson C.A., Leonard W.J., Blanchard D.K. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol. 150:1993;960.
79. Girard D., Gosselin J., Heitz D., Paquin R., Beaulieu A.D. Effects of interleukin-2 on gene expression in human neutrophils. Blood. 86:1995;1170.
80. Damle R.N., Advani S.H., Gangal S.G. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease. Int J Cancer. 50:1992;192.
81. Dummer R., Posseckert G., Sugamura K., Grundmann H., Burg G. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta and gamma chains. J Interferon Cytokine Res. 16:1996;315.
82. Myawaki T., Seki H., Taga K., Sato H., Taniguchi N. Dissociated production of interleukin-2 and immune (γ) interferon by phytohaemagglutinin stimulated lymphocytes in healthy infants. Clin Exp Immunol. 59:1985;505.
83. Rodriguez-Zapata M., Salmeron Manzano L., Salmeron O.J., Prieto A., Alvarez-Mon M. Defective interferon-gamma production by T-lymphocytes from patients with acute brucellosis. Eur J Clin Invest. 26:1996;136.
84. Giordano C., Caruso C., Panto F., Modica M.A., Zambito A.M., Amato M.P., Galluzzo A. Dissociated production of interleukin-2 and immune gamma-interferon by phytohaemoagglutinin stimulated peripheral mononuclear cells in type 1 (insulin-dependent) diabetes. J Clin Lab Immunol. 27:1988;73.
85. Reinhold U., Wehrmann W., Kukel S., Kreysel H.W. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol. 79:1990;374.
86. O'Sullivan S.T., Lederer J.A., Horgan A.F., Chin D.H., Mannick J.A., Rodrick M.L. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 222:1995;482.
87. Kelly J.L., Lyons A., Soberg C.C., Mannick J.A., Lederer J.A. Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. Surgery. 122:1997;146.
88. Funauchi M., Ikoma S., Enomoto H., Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol. 27:1998;219.